IN2014CN02463A - - Google Patents

Download PDF

Info

Publication number
IN2014CN02463A
IN2014CN02463A IN2463CHN2014A IN2014CN02463A IN 2014CN02463 A IN2014CN02463 A IN 2014CN02463A IN 2463CHN2014 A IN2463CHN2014 A IN 2463CHN2014A IN 2014CN02463 A IN2014CN02463 A IN 2014CN02463A
Authority
IN
India
Prior art keywords
hydrogen atom
pde9
acceptable salt
formula
inhibitory effect
Prior art date
Application number
Other languages
English (en)
Inventor
Yoshihiko Norimine
Kunitoshi Takeda
Koji Hagiwara
Yuichi Suzuki
Yuki Ishihara
Nobuaki Sato
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of IN2014CN02463A publication Critical patent/IN2014CN02463A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IN2463CHN2014 2011-10-07 2012-10-04 IN2014CN02463A (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161544860P 2011-10-07 2011-10-07
US201161550623P 2011-10-24 2011-10-24
US201161558110P 2011-11-10 2011-11-10
US201161580903P 2011-12-28 2011-12-28
PCT/JP2012/075748 WO2013051639A1 (ja) 2011-10-07 2012-10-04 ピラゾロキノリン誘導体

Publications (1)

Publication Number Publication Date
IN2014CN02463A true IN2014CN02463A (pt) 2015-06-19

Family

ID=48043792

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2463CHN2014 IN2014CN02463A (pt) 2011-10-07 2012-10-04

Country Status (33)

Country Link
US (2) US8563565B2 (pt)
EP (1) EP2769980B1 (pt)
JP (1) JP5546693B2 (pt)
KR (1) KR101943680B1 (pt)
CN (1) CN103930423B (pt)
AR (1) AR088235A1 (pt)
AU (1) AU2012319549B2 (pt)
BR (1) BR112014007912B1 (pt)
CA (1) CA2861795C (pt)
CL (1) CL2014000821A1 (pt)
CO (1) CO6910200A2 (pt)
CY (1) CY1117427T1 (pt)
DK (1) DK2769980T3 (pt)
ES (1) ES2568015T3 (pt)
HR (1) HRP20160273T1 (pt)
HU (1) HUE028555T2 (pt)
IL (1) IL231650A (pt)
IN (1) IN2014CN02463A (pt)
JO (1) JO3116B1 (pt)
ME (1) ME02394B (pt)
MX (1) MX358149B (pt)
MY (1) MY167698A (pt)
PE (1) PE20141557A1 (pt)
PH (1) PH12014500580A1 (pt)
PL (1) PL2769980T3 (pt)
RS (1) RS54702B1 (pt)
RU (1) RU2605096C2 (pt)
SG (1) SG11201400717QA (pt)
SI (1) SI2769980T1 (pt)
SM (1) SMT201600108B (pt)
TW (1) TWI562993B (pt)
WO (1) WO2013051639A1 (pt)
ZA (1) ZA201402439B (pt)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015007731B1 (pt) 2011-10-10 2022-05-31 H. Lundbeck A/S Composto, composição farmacêutica que o compreende e uso do mesmo
US9573947B2 (en) 2013-04-05 2017-02-21 Eisai R&D Management Co., Ltd. Salt of pyrazoloquinoline derivative, and crystal thereof
JP6244353B2 (ja) 2013-04-05 2017-12-06 エーザイ・アール・アンド・ディー・マネジメント株式会社 ピリジニルピラゾロキノリン化合物
GB201406486D0 (en) 2014-04-10 2014-05-28 Redx Pharma Ltd Antibacterial compounds
WO2016021192A1 (en) * 2014-08-08 2016-02-11 Eisai R&D Management Co., Ltd. Process for production of (s)-(tetrahydrofuran-3-yl)hydrazine
PT3865484T (pt) 2015-07-07 2024-01-30 H Lundbeck As Inibidor da pde9 com esqueleto de imidazo pirazinona para tratamento de doenças periféricas
WO2017046606A1 (en) * 2015-09-18 2017-03-23 Redx Pharma Plc Antibacterial compounds
CN107056690A (zh) * 2017-03-22 2017-08-18 上海康鹏科技有限公司 一种6‑溴吡啶‑3‑甲醛的制备方法
KR20200010220A (ko) 2017-06-01 2020-01-30 에자이 알앤드디 매니지먼트 가부시키가이샤 피라졸로퀴놀린 유도체를 함유하는 루이소체 질병 치료제
RU2019135834A (ru) 2017-06-01 2021-07-13 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Терапевтическое средство для лечения деменции, представляющее собой комбинацию производного пиразолохинолина и донепезила
SG10202113199RA (en) * 2017-06-01 2021-12-30 Eisai R&D Man Co Ltd Dementia therapeutic agent combining pyrazoloquinoline derivative and memantine
KR20200010211A (ko) * 2017-06-01 2020-01-30 에자이 알앤드디 매니지먼트 가부시키가이샤 Pde9 저해제를 포함하는 약제학적 조성물
CN111630042A (zh) * 2018-01-23 2020-09-04 巴斯夫欧洲公司 吡啶衍生物的卤化
CA3100988A1 (en) 2018-05-25 2019-11-28 Imara Inc. Monohydrate and crystalline forms of 6-[(3s,4s)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl-7h-imidazo[1,5-a]pyrazin-8-one
CA3110680A1 (en) * 2018-08-31 2020-03-05 Imara Inc. Pde9 inhibitors for treating sickle cell disease
JP7497357B2 (ja) * 2018-12-13 2024-06-10 インターベット インターナショナル ベー. フェー. 1-[(3r,4s)-4-シアノテトラヒドロピラン-3-イル]-3-[(2-フルオロ-6-メトキシ-4-ピリジル)アミノ]ピラゾール-4-カルボキサミドの調製方法
IL287499B2 (en) 2019-05-09 2025-11-01 Feinstein Institutes For Medical Research Compounds for use in synthesis of peptidomimetics
WO2020227592A1 (en) 2019-05-09 2020-11-12 The Feinstein Institutes For Medical Research Thiosemicarbazates and uses thereof
US11883461B2 (en) 2019-05-09 2024-01-30 The Feinstein Institutes For Medical Research HMGB1 antagonist treatment of severe sepsis
EP3965792A4 (en) 2019-05-09 2023-01-18 The Feinstein Institutes for Medical Research HMGB1 ANTAGONIST
WO2021150613A1 (en) 2020-01-20 2021-07-29 Incyte Corporation Spiro compounds as inhibitors of kras
AU2021254794A1 (en) * 2020-04-16 2022-12-15 Incyte Corporation Fused tricyclic KRAS inhibitors
US11739102B2 (en) 2020-05-13 2023-08-29 Incyte Corporation Fused pyrimidine compounds as KRAS inhibitors
MX2022016551A (es) 2020-06-30 2023-02-01 Bayer Ag Heteroariloxipiridinas sustituidas, asi como sus sales y su uso como principios activos herbicidas.
US11999752B2 (en) 2020-08-28 2024-06-04 Incyte Corporation Vinyl imidazole compounds as inhibitors of KRAS
US11767320B2 (en) 2020-10-02 2023-09-26 Incyte Corporation Bicyclic dione compounds as inhibitors of KRAS
WO2022204112A1 (en) 2021-03-22 2022-09-29 Incyte Corporation Imidazole and triazole kras inhibitors
MX2024000357A (es) 2021-07-07 2024-02-12 Incyte Corp Compuestos triciclicos como inhibidores de homologo de oncogen viral de sarcoma de rata kirsten (kras).
WO2023287896A1 (en) 2021-07-14 2023-01-19 Incyte Corporation Tricyclic compounds as inhibitors of kras
US12441742B2 (en) 2021-08-31 2025-10-14 Incyte Corporation Naphthyridine compounds as inhibitors of KRAS
WO2023049697A1 (en) 2021-09-21 2023-03-30 Incyte Corporation Hetero-tricyclic compounds as inhibitors of kras
CA3234375A1 (en) 2021-10-01 2023-04-06 Incyte Corporation Pyrazoloquinoline kras inhibitors
CA3235146A1 (en) 2021-10-14 2023-04-20 Incyte Corporation Quinoline compounds as inhibitors of kras

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2426734C2 (ru) * 2003-10-03 2011-08-20 Зм Инновейтив Пропертиз Компани Пиразолопиридины и их аналоги
US20060035920A1 (en) * 2004-05-28 2006-02-16 Millennium Pharmaceuticals, Inc. Chk-1 inhibitors
KR20080046728A (ko) 2005-09-15 2008-05-27 아스카 세이야쿠 가부시키가이샤 복소환 화합물, 그의 제조 방법 및 용도
JP2009184924A (ja) 2006-05-31 2009-08-20 Eisai R & D Management Co Ltd 生物学的試薬用化合物
US8299080B2 (en) * 2006-12-13 2012-10-30 Aska Pharmaceutical Co., Ltd. Substituted imidazo[1,5-A] quinoxalines as a PDE9 inhibitor
RS52166B (sr) 2007-05-11 2012-08-31 Pfizer Inc. Amino-heterociklična jedinjenja
UA105362C2 (en) * 2008-04-02 2014-05-12 Бьорингер Ингельхайм Интернациональ Гмбх 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
MX2011009314A (es) 2009-03-05 2011-10-11 Astellas Pharma Inc Compuesto de quinoxalina.
PT2414363E (pt) 2009-03-31 2014-02-26 Boehringer Ingelheim Int Derivados de 1-heterociclil-1,5-di-hidro-pirazolo[3,4- d]pirimidin-4-ona e sua utilização como moduladores de pde9a
US8880976B2 (en) 2009-09-25 2014-11-04 Stmicroelectronics, Inc. Method and apparatus for encoding LBA information into the parity of a LDPC system
RS54834B1 (sr) * 2010-09-07 2016-10-31 Astellas Pharma Inc Jedinjenja pirazolokvinolina
JP6042060B2 (ja) * 2011-09-26 2016-12-14 サノフイ ピラゾロキノリノン誘導体、その調製および治療上の使用

Also Published As

Publication number Publication date
US8563565B2 (en) 2013-10-22
BR112014007912A2 (pt) 2017-04-04
HUE028555T2 (en) 2016-12-28
IL231650A0 (en) 2014-05-28
NZ622594A (en) 2015-06-26
MX2014003800A (es) 2014-07-28
HRP20160273T1 (hr) 2016-04-08
SMT201600108B (it) 2016-04-29
MY167698A (en) 2018-09-21
EP2769980B1 (en) 2016-02-03
PH12014500580A1 (en) 2014-04-28
RU2605096C2 (ru) 2016-12-20
TWI562993B (en) 2016-12-21
KR101943680B1 (ko) 2019-01-29
IL231650A (en) 2016-05-31
ZA201402439B (en) 2015-03-25
PL2769980T3 (pl) 2016-07-29
PE20141557A1 (es) 2014-11-15
RS54702B1 (sr) 2016-08-31
BR112014007912B1 (pt) 2022-06-07
CA2861795A1 (en) 2013-04-11
AR088235A1 (es) 2014-05-21
AU2012319549A1 (en) 2014-04-24
EP2769980A4 (en) 2015-02-25
JPWO2013051639A1 (ja) 2015-03-30
EP2769980A1 (en) 2014-08-27
JP5546693B2 (ja) 2014-07-09
WO2013051639A1 (ja) 2013-04-11
CA2861795C (en) 2018-12-04
SI2769980T1 (sl) 2016-08-31
US20130296352A1 (en) 2013-11-07
CO6910200A2 (es) 2014-03-31
CY1117427T1 (el) 2017-04-26
CL2014000821A1 (es) 2014-07-25
RU2014112931A (ru) 2015-11-20
AU2012319549B2 (en) 2016-07-28
SG11201400717QA (en) 2014-06-27
HK1199018A1 (en) 2015-06-19
ES2568015T3 (es) 2016-04-27
CN103930423A (zh) 2014-07-16
TW201321379A (zh) 2013-06-01
CN103930423B (zh) 2015-09-16
ME02394B (me) 2016-09-20
JO3116B1 (ar) 2017-09-20
US20130143907A1 (en) 2013-06-06
KR20140082684A (ko) 2014-07-02
DK2769980T3 (en) 2016-04-11
MX358149B (es) 2018-08-07

Similar Documents

Publication Publication Date Title
IN2014CN02463A (pt)
IN2015DN01035A (pt)
CR20150254A (es) Compuestos quimicos
ECSP15012804A (es) Alcoxipirazoles como activadores de guanilato ciclasa soluble
CR20140464A (es) Compuestos de heterociclilo
PE20150666A1 (es) Inhibidores de serina/treonina cinasa
ECSP13013038A (es) Inhibidores sustituidos de acetil-coa carboxilasa
ECSP14013222A (es) Indazoles
DOP2015000289A (es) Compuestos de 3,4-dihidroisoquinolin-2(1h)-ilo
CR20160574A (es) Compuestos de dihidroisoquinolinona sustituida
PE20151162A1 (es) Compuestos heterociclicos inhibidores del colesterol 24-hidroxilasa (ch24h)
EA201592146A1 (ru) Гетероароматические соединения и их применение в качестве лигандов к дофаминовым d1-рецепторам
MX2016001304A (es) Polimorfo de inhibidores de syk.
UY33557A (es) Inhibidores de oxadiazol de la produccion de leucotrieno
CR20140071A (es) Nuevos compuestos de 4-piperidinilo para uso como inhibidores de la tankirasa
ECSP14013221A (es) Fenil-3-aza-biciclo [3.1.0] hex-3-il-metanonas y su uso como medicamento.
MX2013008699A (es) Compuestos para reducir la produccion de beta-amiloide.
IN2014KN01062A (pt)
PE20151669A1 (es) Compuestos de azetidiniloxifenilpirrolidina
CO6440510A2 (es) Profármacos de un derivado de piperidinilo como moduladores de la actividad del receptor de quimiocina
PH12015501146A1 (en) Hydantoin derivative
EA201390374A1 (ru) Гетероциклические соединения для лечения или профилактики расстройств, вызываемых ослабленной нейротрансмиссией серотонина, норэпинефрина или допамина
MX348841B (es) Derivados de pirimidooxazocina como inhibidores de mtor.
IN2015DN02514A (pt)
MX2014005538A (es) 1-piridazinil-hidroxiimino-3-fenil-propanos como agonistas de proteina g-receptor acoplado a acido biliar 1 (gpbar1).